Denali Therapeutics/$DNLI
Denali Therapeutics stock rises after Q3 AVLAYAH sales accelerated and the company forecast Q4 product revenue of $30–32 million, although reported profit included a one-off gain from selling a Priority Review Voucher.
10 hours agoLightyear AI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Denali Therapeutics
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
- Ticker
- $DNLI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 503
- Headquarters
- South San Francisco, United States
- Website
- www.denalitherapeutics.com
DNLI Metrics
BasicAdvanced
$3.1B
-
-$2.83
1.00
-
Price and volume
Market cap
$3.1B
Beta
1
52-week high
$27.30
52-week low
$13.75
Average daily volume
1.8M
Financial strength
Current ratio
8.369
Quick ratio
7.947
Long term debt to equity
0.033
Total debt to equity
0.045
Profitability
EBITDA (TTM)
-526.058
Gross margin (TTM)
-11,021.34%
Net profit margin (TTM)
-14,191.20%
Operating margin (TTM)
-15,037.38%
Effective tax rate (TTM)
-0.02%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-29.15%
Return on equity (TTM)
-54.93%
Valuation
Price to revenue (TTM)
973.961
Price to book
3.72
Price to tangible book (TTM)
3.88
Price to free cash flow (TTM)
-7.528
Free cash flow yield (TTM)
-13.28%
Free cash flow per share (TTM)
-2.584
Growth
Earnings per share change (TTM)
0.92%
3-year revenue growth (CAGR)
-78.10%
3-year earnings per share growth (CAGR)
42.85%
What the Analysts think about DNLI
Analyst ratings (Buy, Hold, Sell) for Denali Therapeutics stock.
Analyst projections of the future price of Denali Therapeutics stock.
Bulls say / Bears say
AVLAYAH net product revenue rose to $17.8 million in its second full commercial quarter, and Denali guided for $30–32 million in the fourth quarter. That suggests the launch is gaining traction. (Denali Therapeutics)
Zafinofusp alfa showed preliminary mean reductions of 80% in cerebrospinal-fluid heparan sulfate and 83% in urine heparan sulfate by week 49. Denali says a 2027 BLA submission is on track for Sanfilippo syndrome type A, which has no approved treatment. (Denali Therapeutics)
Denali ended the third quarter with about $1 billion in cash and marketable securities, while five clinical programmes are expected to report data in 2027. This gives it substantial resources to advance a broad pipeline while investors await those results. (Denali Therapeutics)
BIIB122 failed to slow disease progression in the 648-person Phase 2b LUMA trial and missed its secondary endpoints despite showing target activity. Denali and Biogen have stopped development for idiopathic Parkinson’s disease. (Denali Therapeutics)
Takeda ended its collaboration on DNL593, leaving Denali to advance the FTD programme alone, and Denali has pushed the study readout into 2027. The exit was described as strategic rather than efficacy- or safety-driven, but it still removes a development partner and delays a key catalyst. (Denali Therapeutics)
Q3 net income included a $194 million one-off gain from selling a priority review voucher, while product revenue was $17.8 million against $143.6 million of R&D and selling, general and administrative costs. This shows the commercial launch has not yet covered Denali’s operating cost base. (Denali Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
DNLI Financial Performance
Revenues and expenses
DNLI Earnings Performance
Company profitability
Upcoming events
No upcoming events
DNLI News
AllArticlesVideos
Funds containing DNLI
AllUSDEURGBP
Fund name | Fund size | $DNLI weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.19% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.19% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.09% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.09% |
iShares MSCI World Small Cap$WSML | $9B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.